Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anal cancer: an overview.

Hope E Uronis1, Johanna C Bendell

  • 1Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. hope.uronis@duke.edu

The Oncologist
|May 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Initial testing of a mobile app behavioral pain coping intervention for patients with cancer: Results of a pilot randomized controlled trial.

Journal of psychosocial oncology·2026
Same author

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED): A single-arm phase 2 trial.

Cancer·2025
Same author

Minimum Requirements to Safely Establish and Sustain New Hepatic Arterial Infusion Pump Programs: An International Expert Perspective.

Annals of surgical oncology·2025
Same author

Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET).

Journal of neuroendocrinology·2025
Same author

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors.

Molecular cancer therapeutics·2024
Same author

Hepatic artery infusion for unresectable colorectal cancer liver metastases: Palliation and conversion.

Surgery·2023

Anal cancer incidence is rising, with risk factors including HPV infection and smoking. Current treatment focuses on chemoradiation, reserving surgery for residual disease.

Area of Science:

  • Oncology
  • Epidemiology

Background:

  • Anal cancer, a rare malignancy, has seen a significant incidence increase over the past 25 years.
  • Historically attributed to chronic irritation, its etiology is now understood to involve multiple risk factors.

Observation:

  • Key risk factors identified include human papillomavirus (HPV) infection, anoreceptive intercourse, cigarette smoking, and immunosuppression.
  • While HIV infection is associated with higher anal cancer rates, its direct link is complex due to the high prevalence of HPV in this population.

Findings:

  • The standard treatment has evolved from abdominoperineal resection to concurrent chemoradiation therapy.
  • Surgery is now primarily indicated for patients with persistent or residual anal cancer post-treatment.

Implications:

Related Experiment Videos

  • Understanding these risk factors and treatment shifts is crucial for managing the rising incidence of anal cancer.
  • Further research may clarify the specific role of HIV in anal cancer pathogenesis, distinct from HPV co-infection.